‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thi
Vijay Pande's transition from leading a16z's $4 billion biotech practice to starting his own, smaller venture firm VZVC, marks a significant shift in his approach to investing. By moving to a smaller fund, VZVC, Pande is betting on a more focused and agile strategy, one that leverages AI-native approaches to drive innovation in biotech. This move reflects a broader trend in the venture capital industry, where firms are increasingly looking to specialize and adapt to emerging technologies.
The distinction Pande makes between biology as a "discovery" science versus an "engineering" one is crucial. For years, biotech has been driven by discovery, with scientists seeking to understand the intricacies of biological systems. However, with the advent of AI and machine learning, the field is shifting towards engineering, where biological systems can be designed and optimized. This shift has the potential to unlock new breakthroughs and efficiencies in biotech, but it also requires significant investment in new tools and approaches.
As Pande notes, clinical trials remain "brutally expensive," and it will be interesting to see how VZVC and other firms address this challenge. With AI playing a larger role in biotech, we can expect to see new approaches to clinical trials and drug development emerge. To watch next: how VZVC's AI-native strategy plays out in terms of portfolio company performance and innovation, and whether other firms follow suit in adopting a more focused, specialized approach to biotech investing.
Originally reported by techcrunch.com. URLNews adds analysis for ai & agent economy readers.